pmc-enju-pas Home  

PMC:3342329 / 3136-4458 JSONTXT 24 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T2026 0-13 NN denotes Interleukin-1
T2027 14-22 NN denotes receptor
T2028 23-33 NN denotes antagonist
T2029 34-35 -LRB- denotes (
T2030 35-41 NN denotes IL-1Ra
T2031 41-42 -RRB- denotes )
T2032 42-43 -COMMA- denotes ,
T2033 44-45 DT denotes a
T2034 46-52 NN denotes member
T2035 53-55 IN denotes of
T2036 56-59 DT denotes the
T2037 60-64 NN denotes IL-1
T2038 65-71 NN denotes family
T2039 71-72 -COMMA- denotes ,
T2040 73-75 VB denotes is
T2041 76-77 DT denotes a
T2042 78-87 RB denotes naturally
T2043 88-97 VB denotes occurring
T2044 98-106 NN denotes cytokine
T2045 107-111 WDT denotes that
T2046 112-125 RB denotes competitively
T2047 126-132 VB denotes blocks
T2048 133-136 DT denotes the
T2049 137-141 NN denotes IL-1
T2050 142-150 NN denotes receptor
T2051 151-152 -LRB- denotes [
T2052 152-154 CD denotes 13
T2053 154-155 -RRB- denotes ]
T2054 157-164 IN denotes Because
T2055 165-171 NN denotes IL-1Ra
T2056 172-175 VB denotes has
T2057 176-180 VB denotes been
T2058 181-186 VB denotes shown
T2059 187-189 TO denotes to
T2060 190-197 VB denotes inhibit
T2061 198-203 NN denotes tumor
T2062 204-215 NN denotes progression
T2063 216-218 IN denotes by
T2064 219-228 VB denotes promoting
T2065 229-238 JJ denotes antitumor
T2066 239-245 JJ denotes immune
T2067 246-255 NN denotes responses
T2068 256-259 CC denotes and
T2069 260-262 IN denotes by
T2070 263-272 VB denotes enhancing
T2071 273-276 DT denotes the
T2072 277-285 NN denotes activity
T2073 286-288 IN denotes of
T2074 289-301 NN denotes chemotherapy
T2075 301-302 -COMMA- denotes ,
T2076 303-311 JJ denotes numerous
T2077 312-319 NN denotes studies
T2078 320-324 VB denotes have
T2079 325-333 VB denotes examined
T2080 334-337 DT denotes the
T2081 338-345 NN denotes ability
T2082 346-348 IN denotes of
T2083 349-355 NN denotes IL-1Ra
T2084 356-358 TO denotes to
T2085 359-364 VB denotes block
T2086 365-370 NN denotes tumor
T2087 371-382 NN denotes progression
T2088 384-390 NN denotes IL-1Ra
T2089 391-401 NN denotes expression
T2090 402-405 VB denotes was
T2091 406-413 VB denotes reduced
T2092 414-416 IN denotes in
T2093 417-425 NN denotes prostate
T2094 426-427 -LRB- denotes [
T2095 427-429 CD denotes 14
T2096 429-430 -RRB- denotes ]
T2097 430-431 -COMMA- denotes ,
T2098 432-438 NN denotes breast
T2099 439-440 -LRB- denotes [
T2100 440-442 CD denotes 15
T2101 442-443 -RRB- denotes ]
T2102 443-444 -COMMA- denotes ,
T2103 445-448 CC denotes and
T2104 449-453 NN denotes skin
T2105 454-460 NN denotes cancer
T2106 461-462 -LRB- denotes [
T2107 462-464 CD denotes 16
T2108 464-465 -RRB- denotes ]
T2109 467-469 PRP denotes It
T2110 470-473 VB denotes was
T2111 474-478 RB denotes also
T2112 479-487 VB denotes reported
T2113 488-492 IN denotes that
T2114 493-503 JJ denotes endogenous
T2115 504-510 NN denotes IL-1Ra
T2116 511-520 JJ denotes deficient
T2117 521-525 NN denotes mice
T2118 526-535 VB denotes developed
T2119 536-546 JJ denotes aggressive
T2120 547-553 NN denotes tumors
T2121 554-563 VB denotes following
T2122 564-572 NN denotes exposure
T2123 573-575 TO denotes to
T2124 576-587 NN denotes carcinogens
T2125 588-589 -LRB- denotes [
T2126 589-591 CD denotes 17
T2127 591-592 -RRB- denotes ]
T2128 594-603 RB denotes Meanwhile
T2129 603-604 -COMMA- denotes ,
T2130 605-618 NN denotes proliferation
T2131 619-621 IN denotes of
T2132 622-625 DT denotes the
T2133 626-634 NN denotes melanoma
T2134 635-640 NN denotes cells
T2135 641-645 WDT denotes that
T2136 646-650 VB denotes were
T2137 651-661 VB denotes transduced
T2138 662-666 IN denotes with
T2139 667-673 NN denotes IL-1Ra
T2140 674-678 NN denotes gene
T2141 679-682 VB denotes was
T2142 683-690 VB denotes reduced
T2143 691-694 CC denotes and
T2144 695-704 VB denotes inhibited
T2145 705-713 NN denotes melanoma
T2146 714-725 NN denotes development
T2147 726-727 -LRB- denotes [
T2148 727-729 CD denotes 18
T2149 729-730 -RRB- denotes ]
T2150 732-737 NN denotes IL-1R
T2151 738-746 NN denotes blockade
T2152 747-751 RB denotes also
T2153 752-759 VB denotes reduced
T2154 760-767 JJ denotes hepatic
T2155 768-773 NN denotes tumor
T2156 774-780 NN denotes growth
T2157 781-782 -LRB- denotes [
T2158 782-784 CD denotes 19
T2159 784-785 -RRB- denotes ]
T2160 787-795 RB denotes Moreover
T2161 795-796 -COMMA- denotes ,
T2162 797-799 PRP denotes it
T2163 800-803 VB denotes has
T2164 804-808 RB denotes also
T2165 809-813 VB denotes been
T2166 814-822 VB denotes reported
T2167 823-827 IN denotes that
T2168 828-834 NN denotes IL-1Ra
T2169 835-842 VB denotes reduces
T2170 843-855 NN denotes fibrosarcoma
T2171 856-867 NN denotes development
T2172 868-869 -LRB- denotes [
T2173 869-871 CD denotes 20
T2174 871-872 -RRB- denotes ]
T2175 872-873 -COMMA- denotes ,
T2176 874-877 NN denotes B16
T2177 878-886 NN denotes melanoma
T2178 887-893 NN denotes growth
T2179 894-897 CC denotes and
T2180 898-908 NN denotes metastasis
T2181 909-910 -LRB- denotes [
T2182 910-912 CD denotes 21
T2183 912-913 -RRB- denotes ]
T2184 913-914 -COMMA- denotes ,
T2185 915-920 NN denotes colon
T2186 921-935 NN denotes adenocarcinoma
T2187 936-942 NN denotes growth
T2188 943-944 -LRB- denotes [
T2189 944-946 CD denotes 22
T2190 946-947 -RRB- denotes ]
T2191 947-948 -COMMA- denotes ,
T2192 949-952 CC denotes and
T2193 953-957 NN denotes skin
T2194 958-964 NN denotes cancer
T2195 965-976 NN denotes development
T2196 977-978 -LRB- denotes [
T2197 978-980 CD denotes 23
T2198 980-981 -RRB- denotes ]
T2199 983-987 NN denotes IL-1
T2200 988-996 NN denotes knockout
T2201 997-1001 NN denotes mice
T2202 1002-1010 VB denotes injected
T2203 1011-1015 IN denotes with
T2204 1016-1024 NN denotes melanoma
T2205 1025-1031 VB denotes failed
T2206 1032-1034 TO denotes to
T2207 1035-1042 VB denotes develop
T2208 1043-1048 JJ denotes solid
T2209 1049-1055 NN denotes tumors
T2210 1056-1057 -LRB- denotes [
T2211 1057-1059 CD denotes 24
T2212 1059-1060 -RRB- denotes ]
T2213 1062-1064 PRP denotes It
T2214 1065-1068 VB denotes was
T2215 1069-1073 RB denotes also
T2216 1074-1079 VB denotes found
T2217 1080-1084 IN denotes that
T2218 1085-1091 NN denotes IL-1Ra
T2219 1091-1092 -COMMA- denotes ,
T2220 1093-1101 VB denotes combined
T2221 1102-1106 IN denotes with
T2222 1107-1119 NN denotes temozolomide
T2223 1120-1123 CC denotes and
T2224 1124-1133 NN denotes docetaxel
T2225 1134-1146 NN denotes chemotherapy
T2226 1146-1147 -COMMA- denotes ,
T2227 1148-1160 VB denotes demonstrated
T2228 1161-1165 RB denotes more
T2229 1166-1177 JJ denotes significant
T2230 1178-1187 JJ denotes antitumor
T2231 1188-1196 NN denotes activity
T2232 1197-1204 IN denotes against
T2233 1205-1208 NN denotes B16
T2234 1209-1217 NN denotes melanoma
T2235 1218-1223 NN denotes cells
T2236 1224-1226 FW denotes in
T2237 1227-1231 FW denotes vivo
T2238 1232-1233 -LRB- denotes [
T2239 1233-1235 CD denotes 25
T2240 1235-1236 -RRB- denotes ]
T2241 1238-1243 DT denotes These
T2242 1244-1248 NN denotes data
T2243 1249-1257 VB denotes indicate
T2244 1258-1262 IN denotes that
T2245 1263-1269 NN denotes IL-1Ra
T2246 1270-1272 VB denotes is
T2247 1273-1282 JJ denotes important
T2248 1283-1285 IN denotes as
T2249 1286-1287 DT denotes a
T2250 1288-1293 NN denotes tumor
T2251 1294-1300 NN denotes growth
T2252 1301-1312 VB denotes suppressing
T2253 1313-1321 NN denotes cytokine
R1099 T2028 T2026 arg1Of antagonist,Interleukin-1
R1100 T2028 T2027 arg1Of antagonist,receptor
R1101 T2028 T2029 arg1Of antagonist,(
R1102 T2028 T2032 arg1Of antagonist,","
R1103 T2028 T2040 arg1Of antagonist,is
R1104 T2030 T2029 arg2Of IL-1Ra,(
R1105 T2031 T2029 arg3Of ),(
R1106 T2034 T2032 arg2Of member,","
R1107 T2034 T2033 arg1Of member,a
R1108 T2034 T2035 arg1Of member,of
R1109 T2038 T2035 arg2Of family,of
R1110 T2038 T2036 arg1Of family,the
R1111 T2038 T2037 arg1Of family,IL-1
R1112 T2040 T2039 arg1Of is,","
R1113 T2043 T2042 arg1Of occurring,naturally
R1114 T2044 T2040 arg2Of cytokine,is
R1115 T2044 T2041 arg1Of cytokine,a
R1116 T2044 T2043 arg1Of cytokine,occurring
R1117 T2044 T2045 arg1Of cytokine,that
R1118 T2044 T2047 arg1Of cytokine,blocks
R1119 T2047 T2046 arg1Of blocks,competitively
R1120 T2047 T2051 arg1Of blocks,[
R1121 T2050 T2047 arg2Of receptor,blocks
R1122 T2050 T2048 arg1Of receptor,the
R1123 T2050 T2049 arg1Of receptor,IL-1
R1124 T2052 T2051 arg2Of 13,[
R1125 T2053 T2051 arg3Of ],[
R1126 T2055 T2056 arg1Of IL-1Ra,has
R1127 T2055 T2057 arg1Of IL-1Ra,been
R1128 T2055 T2058 arg2Of IL-1Ra,shown
R1129 T2055 T2060 arg1Of IL-1Ra,inhibit
R1130 T2055 T2064 arg1Of IL-1Ra,promoting
R1131 T2055 T2070 arg1Of IL-1Ra,enhancing
R1132 T2058 T2054 arg2Of shown,Because
R1133 T2058 T2056 arg2Of shown,has
R1134 T2058 T2057 arg2Of shown,been
R1135 T2060 T2058 arg3Of inhibit,shown
R1136 T2060 T2059 arg1Of inhibit,to
R1137 T2060 T2063 arg1Of inhibit,by
R1138 T2060 T2069 arg1Of inhibit,by
R1139 T2062 T2060 arg2Of progression,inhibit
R1140 T2062 T2061 arg1Of progression,tumor
R1141 T2063 T2068 arg1Of by,and
R1142 T2064 T2063 arg2Of promoting,by
R1143 T2067 T2064 arg2Of responses,promoting
R1144 T2067 T2065 arg1Of responses,antitumor
R1145 T2067 T2066 arg1Of responses,immune
R1146 T2069 T2068 arg2Of by,and
R1147 T2070 T2069 arg2Of enhancing,by
R1148 T2072 T2070 arg2Of activity,enhancing
R1149 T2072 T2071 arg1Of activity,the
R1150 T2072 T2073 arg1Of activity,of
R1151 T2074 T2073 arg2Of chemotherapy,of
R1152 T2077 T2076 arg1Of studies,numerous
R1153 T2077 T2078 arg1Of studies,have
R1154 T2077 T2079 arg1Of studies,examined
R1155 T2079 T2054 arg1Of examined,Because
R1156 T2079 T2075 arg1Of examined,","
R1157 T2079 T2078 arg2Of examined,have
R1158 T2081 T2079 arg2Of ability,examined
R1159 T2081 T2080 arg1Of ability,the
R1160 T2081 T2082 arg1Of ability,of
R1161 T2081 T2084 modOf ability,to
R1162 T2083 T2082 arg2Of IL-1Ra,of
R1163 T2085 T2084 arg1Of block,to
R1164 T2087 T2085 arg2Of progression,block
R1165 T2087 T2086 arg1Of progression,tumor
R1166 T2089 T2088 arg1Of expression,IL-1Ra
R1167 T2089 T2090 arg1Of expression,was
R1168 T2089 T2091 arg2Of expression,reduced
R1169 T2091 T2090 arg2Of reduced,was
R1170 T2091 T2092 arg1Of reduced,in
R1171 T2093 T2094 arg1Of prostate,[
R1172 T2093 T2097 arg1Of prostate,","
R1173 T2095 T2094 arg2Of 14,[
R1174 T2096 T2094 arg3Of ],[
R1175 T2097 T2103 arg1Of ",",and
R1176 T2098 T2097 arg2Of breast,","
R1177 T2098 T2099 arg1Of breast,[
R1178 T2100 T2099 arg2Of 15,[
R1179 T2101 T2099 arg3Of ],[
R1180 T2103 T2092 arg2Of and,in
R1181 T2103 T2102 arg1Of and,","
R1182 T2105 T2103 arg2Of cancer,and
R1183 T2105 T2104 arg1Of cancer,skin
R1184 T2105 T2106 arg1Of cancer,[
R1185 T2107 T2106 arg2Of 16,[
R1186 T2108 T2106 arg3Of ],[
R1187 T2109 T2110 arg1Of It,was
R1188 T2109 T2112 arg2Of It,reported
R1189 T2112 T2110 arg2Of reported,was
R1190 T2112 T2111 arg1Of reported,also
R1191 T2117 T2114 arg1Of mice,endogenous
R1192 T2117 T2115 arg1Of mice,IL-1Ra
R1193 T2117 T2116 arg1Of mice,deficient
R1194 T2117 T2118 arg1Of mice,developed
R1195 T2118 T2112 arg3Of developed,reported
R1196 T2118 T2113 arg1Of developed,that
R1197 T2118 T2121 arg1Of developed,following
R1198 T2120 T2118 arg2Of tumors,developed
R1199 T2120 T2119 arg1Of tumors,aggressive
R1200 T2122 T2121 arg2Of exposure,following
R1201 T2122 T2123 arg1Of exposure,to
R1202 T2124 T2123 arg2Of carcinogens,to
R1203 T2124 T2125 arg1Of carcinogens,[
R1204 T2126 T2125 arg2Of 17,[
R1205 T2127 T2125 arg3Of ],[
R1206 T2130 T2131 arg1Of proliferation,of
R1207 T2130 T2141 arg1Of proliferation,was
R1208 T2130 T2142 arg2Of proliferation,reduced
R1209 T2130 T2144 arg1Of proliferation,inhibited
R1210 T2134 T2131 arg2Of cells,of
R1211 T2134 T2132 arg1Of cells,the
R1212 T2134 T2133 arg1Of cells,melanoma
R1213 T2134 T2135 arg1Of cells,that
R1214 T2134 T2136 arg1Of cells,were
R1215 T2134 T2137 arg2Of cells,transduced
R1216 T2137 T2136 arg2Of transduced,were
R1217 T2137 T2138 arg1Of transduced,with
R1218 T2140 T2138 arg2Of gene,with
R1219 T2140 T2139 arg1Of gene,IL-1Ra
R1220 T2142 T2141 arg2Of reduced,was
R1221 T2142 T2143 arg1Of reduced,and
R1222 T2143 T2128 arg1Of and,Meanwhile
R1223 T2143 T2129 arg1Of and,","
R1224 T2143 T2147 arg1Of and,[
R1225 T2144 T2143 arg2Of inhibited,and
R1226 T2146 T2144 arg2Of development,inhibited
R1227 T2146 T2145 arg1Of development,melanoma
R1228 T2148 T2147 arg2Of 18,[
R1229 T2149 T2147 arg3Of ],[
R1230 T2151 T2150 arg1Of blockade,IL-1R
R1231 T2151 T2153 arg1Of blockade,reduced
R1232 T2153 T2152 arg1Of reduced,also
R1233 T2156 T2153 arg2Of growth,reduced
R1234 T2156 T2154 arg1Of growth,hepatic
R1235 T2156 T2155 arg1Of growth,tumor
R1236 T2156 T2157 arg1Of growth,[
R1237 T2158 T2157 arg2Of 19,[
R1238 T2159 T2157 arg3Of ],[
R1239 T2162 T2163 arg1Of it,has
R1240 T2162 T2165 arg1Of it,been
R1241 T2162 T2166 arg2Of it,reported
R1242 T2166 T2160 arg1Of reported,Moreover
R1243 T2166 T2161 arg1Of reported,","
R1244 T2166 T2163 arg2Of reported,has
R1245 T2166 T2164 arg1Of reported,also
R1246 T2166 T2165 arg2Of reported,been
R1247 T2168 T2169 arg1Of IL-1Ra,reduces
R1248 T2169 T2166 arg3Of reduces,reported
R1249 T2169 T2167 arg1Of reduces,that
R1250 T2169 T2196 arg1Of reduces,[
R1251 T2171 T2172 arg1Of development,[
R1252 T2171 T2175 arg1Of development,","
R1253 T2173 T2172 arg2Of 20,[
R1254 T2174 T2172 arg3Of ],[
R1255 T2177 T2175 arg2Of melanoma,","
R1256 T2177 T2176 arg1Of melanoma,B16
R1257 T2178 T2179 arg1Of growth,and
R1258 T2179 T2170 arg1Of and,fibrosarcoma
R1259 T2179 T2171 arg1Of and,development
R1260 T2179 T2177 arg1Of and,melanoma
R1261 T2179 T2181 arg1Of and,[
R1262 T2179 T2184 arg1Of and,","
R1263 T2180 T2179 arg2Of metastasis,and
R1264 T2182 T2181 arg2Of 21,[
R1265 T2183 T2181 arg3Of ],[
R1266 T2184 T2192 arg1Of ",",and
R1267 T2187 T2184 arg2Of growth,","
R1268 T2187 T2185 arg1Of growth,colon
R1269 T2187 T2186 arg1Of growth,adenocarcinoma
R1270 T2187 T2188 arg1Of growth,[
R1271 T2189 T2188 arg2Of 22,[
R1272 T2190 T2188 arg3Of ],[
R1273 T2192 T2169 arg2Of and,reduces
R1274 T2192 T2191 arg1Of and,","
R1275 T2195 T2192 arg2Of development,and
R1276 T2195 T2193 arg1Of development,skin
R1277 T2195 T2194 arg1Of development,cancer
R1278 T2197 T2196 arg2Of 23,[
R1279 T2198 T2196 arg3Of ],[
R1280 T2201 T2199 arg1Of mice,IL-1
R1281 T2201 T2200 arg1Of mice,knockout
R1282 T2201 T2202 arg2Of mice,injected
R1283 T2201 T2205 arg1Of mice,failed
R1284 T2201 T2207 arg1Of mice,develop
R1285 T2202 T2203 arg1Of injected,with
R1286 T2204 T2203 arg2Of melanoma,with
R1287 T2207 T2205 arg2Of develop,failed
R1288 T2207 T2206 arg1Of develop,to
R1289 T2209 T2207 arg2Of tumors,develop
R1290 T2209 T2208 arg1Of tumors,solid
R1291 T2209 T2210 arg1Of tumors,[
R1292 T2211 T2210 arg2Of 24,[
R1293 T2212 T2210 arg3Of ],[
R1294 T2213 T2214 arg1Of It,was
R1295 T2213 T2216 arg2Of It,found
R1296 T2216 T2214 arg2Of found,was
R1297 T2216 T2215 arg1Of found,also
R1298 T2218 T2219 arg1Of IL-1Ra,","
R1299 T2218 T2220 arg2Of IL-1Ra,combined
R1300 T2218 T2223 arg1Of IL-1Ra,and
R1301 T2220 T2221 arg1Of combined,with
R1302 T2222 T2221 arg2Of temozolomide,with
R1303 T2223 T2227 arg1Of and,demonstrated
R1304 T2225 T2223 arg2Of chemotherapy,and
R1305 T2225 T2224 arg1Of chemotherapy,docetaxel
R1306 T2227 T2216 arg3Of demonstrated,found
R1307 T2227 T2217 arg1Of demonstrated,that
R1308 T2227 T2226 arg1Of demonstrated,","
R1309 T2227 T2232 arg1Of demonstrated,against
R1310 T2227 T2238 arg1Of demonstrated,[
R1311 T2229 T2228 arg1Of significant,more
R1312 T2231 T2227 arg2Of activity,demonstrated
R1313 T2231 T2229 arg1Of activity,significant
R1314 T2231 T2230 arg1Of activity,antitumor
R1315 T2235 T2232 arg2Of cells,against
R1316 T2235 T2233 arg1Of cells,B16
R1317 T2235 T2234 arg1Of cells,melanoma
R1318 T2235 T2237 arg1Of cells,vivo
R1319 T2237 T2236 arg1Of vivo,in
R1320 T2239 T2238 arg2Of 25,[
R1321 T2240 T2238 arg3Of ],[
R1322 T2242 T2241 arg1Of data,These
R1323 T2242 T2243 arg1Of data,indicate
R1324 T2245 T2246 arg1Of IL-1Ra,is
R1325 T2245 T2247 arg1Of IL-1Ra,important
R1326 T2246 T2243 arg2Of is,indicate
R1327 T2246 T2244 arg1Of is,that
R1328 T2247 T2246 arg2Of important,is
R1329 T2247 T2248 arg1Of important,as
R1330 T2253 T2248 arg2Of cytokine,as
R1331 T2253 T2249 arg1Of cytokine,a
R1332 T2253 T2250 arg1Of cytokine,tumor
R1333 T2253 T2251 arg1Of cytokine,growth
R1334 T2253 T2252 arg1Of cytokine,suppressing